Regulatory status

Classification differs by jurisdiction, and for several compounds it differs by form and by route of administration as well. A position recorded for one territory does not describe the position in another. 25 entries are recorded across 6 jurisdictions.

How supply classifications work

United States

CompoundClassificationVerified
SemaglutideApproved medicine2026-08-05
TirzepatideApproved medicine2026-08-05
OrforglipronApproved medicine2026-07-30
RetatrutideInvestigational — no marketing authorisation2026-07-30
GHK-CuCosmetic ingredient2026-07-30
AHK-CuNo established classification2026-07-30
NAD+No established classification2026-07-30

European Union

CompoundClassificationVerified
SemaglutideApproved medicine2026-07-30
TirzepatideApproved medicine2026-07-30
OrforglipronInvestigational — no marketing authorisation2026-07-30
RetatrutideInvestigational — no marketing authorisation2026-07-30
GHK-CuCosmetic ingredient2026-07-31
AHK-CuCosmetic ingredient2026-07-31
NAD+Food supplement ingredient2026-07-30

United Kingdom

CompoundClassificationVerified
SemaglutideApproved medicine2026-07-30
TirzepatideApproved medicine2026-07-30
OrforglipronInvestigational — no marketing authorisation2026-07-30
RetatrutideInvestigational — no marketing authorisation2026-07-30
GHK-CuCosmetic ingredient2026-07-31
AHK-CuCosmetic ingredient2026-07-31
NAD+No established classification2026-07-30

Australia

CompoundClassificationVerified
RetatrutideInvestigational — no marketing authorisation2026-07-30
NAD+No established classification2026-07-30

Canada

CompoundClassificationVerified
RetatrutideInvestigational — no marketing authorisation2026-07-30

Switzerland

CompoundClassificationVerified
RetatrutideInvestigational — no marketing authorisation2026-07-30